Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-246.41	-274.45	-342.99	-234.63	-183.12	-250.22
Depreciation & Amortization	10.43	11.54	19.63	20.25	18.02	13.62
Stock-Based Compensation	40.1	41.83	33.14	47.08	81.92	62.2
Other Adjustments	-22.73	80.95	130.95	0.18	-4.37	44.13
Changes in Accounts Payable	1.7	-2.34	-3.23	1.46	0.67	0.09
Changes in Accrued Expenses	-1.42	-7.64	-1.25	-0.72	-0.46	4.54
Changes in Unearned Revenue	-	-	-	-	-84.65	-10.51
Changes in Other Operating Activities	-1.7	0.09	1.36	2.68	2.43	9.89
Operating Cash Flow	-133.8	-150.02	-162.39	-163.69	-169.56	-126.25
Capital Expenditures	-0.62	-0.78	-0.46	-2.69	-24.28	-65.5
Sale of Property, Plant & Equipment	0.29	0.29	-	-	-	-
Purchases of Investments	-231.67	-278.9	-394.71	-476.88	-406.32	-673.47
Proceeds from Sale of Investments	275.21	374.68	548.94	663.61	419.05	617.4
Payments for Business Acquisitions	-	-41.2	-31.35	-	-	-
Investing Cash Flow	2.01	54.1	122.42	184.05	-11.54	-121.57
Issuance of Common Stock	101.99	50.41	1.4	2.2	11.1	401.24
Repurchase of Common Stock	-0	-0	-0.08	-0.46	-0.46	-
Net Common Stock Issued (Repurchased)	101.99	50.41	1.33	1.74	10.64	401.24
Financing Cash Flow	102.13	50.41	1.33	1.74	10.64	401.24
Net Cash Flow	-29.66	-45.52	-38.64	22.1	-170.46	153.42
Free Cash Flow	-134.42	-150.8	-162.86	-166.38	-193.83	-191.75
FCF Margin	-433610.00%	-418900.00%	-266980.00%	-127985.00%	-228.89%	-1800.50%
Free Cash Flow Per Share	-7.13	-8.82	-12.46	-13.26	-15.69	-28.22
Levered Free Cash Flow	-238.02	-273.58	-326.95	-213.65	-271.39	-298.08
Unlevered Free Cash Flow	-247.92	-268.54	-342.71	-226.02	-275.33	-262.64

Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q